Table 3 Clinical trials investigating combination of anti-angiogenic therapy, immune checkpoint blockades, and radiotherapy in patients with solid cancer.
Clinical trials gov number | Phase | Disease setting | Agents | RT | Primary endpoint | Estimated study completion date | Recruitment status | Patient population | most common AEs | AEs (total, Gr 3–5) |
|---|---|---|---|---|---|---|---|---|---|---|
NCT04609293 | Observational study | Locally advanced/metastatic or recurrent RCCs | Camrelizumab+ Apatinib | Hyperfractionated RT (marginal dose of 50 Gy/2 Gy/25 f and tumor center dose of local hyperfraction 24–32 Gy/8–12 Gy/3–4 f) | ORR | 2024 | Not yet recruiting | 30 | – | – |
NCT02313272 | I | Recurrent HGGs | Pembrolizumab + bevacizumab | HFSRT (30 Gy/5 f) | Safety and tolerability | 2020 | Active, not recruiting | 32 | Proteinuria, increased alanine aminotransferase, fatigue, hypertension | Gr 3: 12 (34.4%) |
NCT02829931 | I | Recurrent HGGs | Ipilimumab+Nivolumab+ bevacizumab | HFSRT (30 Gy/5 f) | Safety and tolerability | 2022 | Recruiting | 26 | – | – |
